Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer

Inclusion Criteria

• Patients aged 20 years or older at time of consent
• H. pylori-positive patients meeting both of the following criteria:• Assessed as H. pylori-positive by rapid urease test and/or 13C-urea breath test at pre-study examination, • Assessed as H. pylori-antibody-positive by urine-based test after obtaining informed consent
• Patients endoscopically diagnosed with gastric ulcer meeting the following criteria:• Active (A1- or A2-stage by Sakita/Miwa classification）, • Solitary, • Longitudinal diameter: ->5 mm
• Patients who have not received proton pump inhibitors (PPIs), antibacterial agents, or antiprotozoal agents within 1 week prior to endoscopy

Exclusion Criteria

• Patients who have previously received H. pylori eradication therapy
• Patients with acute gastric ulcer
• Patients with linear ulcer
• Patients with complication of duodenal ulcer (excluding cicatrix)
• Patients who have undergone upper-GI tract or vagal nerve resection
• Patients who are unsuitable for pharmacotherapy, e.g., with perforation or pyloric stenosis
• Patients with gastric ulcer considered likely to induce massive hemorrhage (e.g., with obviously exposed blood vessels at lesion sites)
• Patients with a history of amoxicillin shock
• Patients with infectious mononucleosis
• Patients with severe renal disorders
• Patients with a history of hypersensitivity to penicillins, clarithromycin, lansoprazole, or rebamipide
• Patients who have been treated with drugs contraindicated to clarithromycin, such as terfenadine, cisapride, and pimozide
• Patients who are pregnant, possibly pregnant, lactating, or who desire to become pregnant during the study
• Patients who are otherwise judged inappropriate for inclusion in the study by the investigator or subinvestigator